Cellectis (CLLS), a clinical-stage biotechnology company developing gene-edited cell and gene therapies, reported financial results for the second quarter of 2026.
For Q2 2026, the company reported cash, cash equivalents and fixed-term deposits of $169 million as of June 30, 2026, providing runway into the fourth quarter of 2027. This compares with $145 million in cash and equivalents reported in Q2 2025, reflecting strengthened liquidity year-over-year.
The company continues to advance its allogeneic CAR-T pipeline, with key updates presented at the European Hematology Association (EHA) 2026 Annual Congress.
Pipeline Highlights
Lasme-cel, studied in the BALLI-01 trial for relapsed/refractory B-cell acute lymphoblastic leukemia, is now in a pivotal Phase 2 program. The FDA granted RMAT designation in June 2026, recognizing its potential to address unmet need in CD22-positive B-ALL. Full Phase 1 data presented at the EHA included 45 patients treated in third line and beyond, with 15 at the recommended Phase 2 dose and 7 in the target Phase 2 population. Results showed encouraging efficacy, with objective response rate of 67% (ORR) and complete response (CR) rate of 56% supporting advancement. Median duration of response was consistent with durable benefit, and safety was manageable. An interim Phase 2 analysis is expected in Q4 2026.
Eti-cel, under the evaluation NATHALI-01 trial for relapsed/refractory non-Hodgkin lymphoma, remains in Phase 1. Translational data presented at EHA 2026 highlighted key drivers of response, with ORR of 46% and CR rate of 31% showing activity in heavily pretreated patients. Full Phase 1 dataset expected in Q4 2026.
CEO André Choulika noted that both lasme-cel and eti-cel results are promising for patients with r/r B-cell malignancies, underscoring the company's focus on advancing new therapeutic options.
CLLS has traded between $2.35 and $5.48 over the past year. The stock closed Thursday's trading at $2.69, down 3.58%. During afterhours trading session, the stock is at $2.87, up 6.69%.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.